CoChat
Sign Up
Cited by 34Bariatric Surgery and OutcomesGrowth Hormone and Insulin-like Growth FactorsNutrition and Health in Aging

The DOI matches its Crossref record; the references it cites are not checked yet.

Growth Hormone Treatment Prevents Loss of Lean Mass after Bariatric Surgery in Morbidly Obese Patients: Results of a Pilot, Open, Prospective, Randomized, Controlled Study

Savastano, Silvia, Di Somma, Carolina, Angrisani, Luigi, Orio, Francesco, Longobardi, Salvatore, Lombardi, Gaetano, Colao, Annamaria·2009·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2008-1476
Open this paper in CoChat — free account

Abstract

CONTEXT: The loss of lean body mass (LBM) negatively influences the outcome in bariatric surgery. Impaired GH secretion is frequent in obese patients. OBJECTIVE: Our objective was to investigate if GH treatment prevents LBM loss in the early postoperative period. DESIGN: This was an open, prospective, randomized, and controlled study. PATIENTS: A total of 24 women (body mass index: 44.4 +/- 7.6 kg/m(2), aged 36.8 +/- 11.7 yr) undergoing laparoscopic-adjustable silicone gastric banding (LASGB) and with GH deficiency after LASGB was included in the study. TREATMENT PROTOCOL: Group A (n = 12) included a standardized diet regimen and exercise program plus recombinant human GH (0.5 +/- 0.13 mg every day), and group B (n = 12) included a standardized diet regimen and exercise program. The follow-up duration was 6 months. RESULTS: The excess of body weight loss did not differ between groups A and B after 3 and 6 months. At 3 months, LBM loss was lower (P < 0.0001) and fat mass (FM) loss was higher (P = 0.02) in group A than group B. At 3 and 6 months, appendicular skeletal muscle mass loss was lower (P = 0.000) in group A than group B. At 3 (P = 0.0003 and 0.0005, respectively) and 6 months (P < 0.0001 and 0.0002, respectively), the percent changes of FM and lean body mass were significantly higher in group A than group B. In both groups fasting and postglucose area under the plasma concentration-time curve insulin significantly reduced. The homeostasis model assessment of insulin and insulin sensitivity indexes and total to high-density lipoprotein cholesterol ratio improved only in group A. CONCLUSIONS: GH treatment for 6 months after LASGB reduces loss in LBM and appendicular skeletal muscle mass during a standardized program of low-calorie diet and physical exercise program, with improvement of lipid profile and without a deterioration of glucose tolerance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2008-1476

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 55 · Cited by 34

Research works printed but not linked: 46

  1. Malnick, 2006, The medical complications of obesity., QJM, 99, 565, 10.1093/qjmed/hcl085 · DOI · Paper page
  2. Hensrud, 2006, Extreme obesity: a new medical crisis in the United States, Mayo Clin Proc, 81, S5, 10.1016/S0025-6196(11)61175-0 · DOI
  3. O'Brien, 2006, Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial., Ann Intern Med, 144, 625, 10.7326/0003-4819-144-9-200605020-00005 · DOI · Paper page
  4. Kral, 2007, Surgical treatment of obesity., Nat Clin Pract Endocrinol Metab, 3, 574, 10.1038/ncpendmet0563 · DOI
  5. Shah, 2006, Review: long-term impact of bariatric surgery on body weight, comorbidities, and nutritional status., J Clin Endocrinol Metab, 91, 4223, 10.1210/jc.2006-0557 · DOI
  6. Russell-Jones, 1993, The effects of growth hormone on protein metabolism in adult growth hormone deficient patients., Clin Endocrinol (Oxf), 38, 427, 10.1111/j.1365-2265.1993.tb00525.x · DOI
  7. Møller, 1995, Metabolic effects of growth hormone in humans, Metabolism, 44, 33, 10.1016/0026-0495(95)90218-X · DOI
  8. J Clin Endocrinol Metab, 83, 379
  9. Frystyk, 2004, Free insulin-like growth factors: measurements and relationships to growth hormone secretion and glucose homeostasis., Growth Horm IGF Res, 14, 337, 10.1016/j.ghir.2004.06.001 · DOI
  10. Maccario, 1997, Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency., Int J Obes Relat Metab Disord, 21, 27, 10.1038/sj.ijo.0800356 · DOI
  11. Scacchi, 1999, Growth hormone in obesity., Int J Obes, 23, 262, 10.1038/sj.ijo.0800807 · DOI
  12. Savastano, 2006, GH insufficiency in obese patients, J Endocrinol Invest 29(Suppl):, 42
  13. Franco, 2001, Visceral obesity and the role of the somatotropic axis in the development of metabolic complications, Growth Horm IGF Res, 11, S97, 10.1016/S1096-6374(01)80016-2 · DOI
  14. Rasmussen, 1995, Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects., J Clin Endocrinol Metab [Erratum (1995) 80:2446], 80, 1407
  15. Maccario, 1999, Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients., Int J Obes Relat Metab Disord, 23, 612, 10.1038/sj.ijo.0800889 · DOI
  16. Voorhoeve, 2006, Association between an IGF-I gene polymorphism and body fatness: differences between generations., Eur J Endocrinol, 154, 379, 10.1530/eje.1.02101 · DOI
  17. Savastano, 2006, Growth hormone status in morbidly obese subjects and correlation with body composition., J Endocrinol Invest, 29, 536, 10.1007/BF03344144 · DOI
  18. Di Somma, 2008, GH and IGF-I deficiency are associated with reduced loss of fat mass after laparoscopic-adjustable silicone gastric banding., Clin Endocrinol (Oxf), 69, 393, 10.1111/j.1365-2265.2008.03183.x · DOI
  19. Corneli, 2005, The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index., Eur J Endocrinol, 153, 257, 10.1530/eje.1.01967 · DOI
  20. Ghigo, 1996, New approach to the diagnosis of growth hormone deficiency in adults., Eur J Endocrinol, 134, 352, 10.1530/eje.0.1340352 · DOI · Paper page
  21. Hu, 1999, Reproducibility and validity of dietary patterns assessed with a food-frequency questionnaire., Am J Clin Nutr, 69, 243, 10.1093/ajcn/69.2.243 · DOI · Paper page
  22. Kuzmak, 1991, A review of seven years’ experience with silicone gastric banding., Obes Surg, 1, 403, 10.1381/096089291765560809 · DOI
  23. Angrisani, 1997, Laparoscopic adjustable silicone gastric banding: preliminary results of Naples experience., Obes Surg, 7, 19, 10.1381/096089297765556178 · DOI
  24. Busetto, 1997, The influence of a new timing strategy of band adjustment on the vomiting frequency and the food consumption of obese women operated with laparoscopic adjustable silicone gastric banding (LAP-BAND)., Obes Surg, 7, 505, 10.1381/096089297765555269 · DOI
  25. Matsuda, 1999, Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp., Diabetes Care, 22, 1462, 10.2337/diacare.22.9.1462 · DOI · Paper page
  26. Diabetes Care, 20, 1183, 10.2337/diacare.20.7.1183 · DOI · Paper page
  27. Van Gaal, 1992, Factors determining energy expenditure during very-low-calorie diets, Am J Clin Nutr, 56, 224S, 10.1093/ajcn/56.1.224S · DOI
  28. Coupaye, 2007, Is lean body mass decreased after obesity treatment by adjustable gastric banding?, Obes Surg, 17, 427, 10.1007/s11695-007-9072-8 · DOI
  29. Møller, 2003, Effects of growth hormone on lipid metabolism in humans, Growth Horm IGF Res, 13, S18, 10.1016/S1096-6374(03)00048-0 · DOI
  30. Colao, 2006, Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy, Growth Horm IGF Res, 16, S41, 10.1016/j.ghir.2006.03.006 · DOI
  31. Johannsson, 1997, Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure., J Clin Endocrinol Metab, 82, 727
  32. Shadid, 2003, Effects of growth hormone administration in human obesity., Obes Res, 11, 170, 10.1038/oby.2003.27 · DOI
  33. Albert, 2004, Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity., J Clin Endocrinol Metab, 89, 695, 10.1210/jc.2003-031264 · DOI
  34. Attallah, 2006, Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy, Growth Horm IGF Res, 16, S62, 10.1016/j.ghir.2006.03.004 · DOI
  35. Tagliaferri, 1998, Metabolic effects of biosynthetic growth hormone treatment in severely energy-restricted obese women., Int J Obes Relat Metab Disord, 22, 836, 10.1038/sj.ijo.0800669 · DOI
  36. Laron, 2006, Long-term IGF-I treatment of children with Laron syndrome increases adiposity., Growth Horm IGF Res, 16, 61, 10.1016/j.ghir.2005.12.001 · DOI
  37. Lund, 1994, Comparative effects of IGF-I and insulin on the glucose transporter system in rat muscle, Am J Physiol, 267, E461
  38. Rosenbaum, 1989, Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH-deficient children., J Clin Endocrinol Metab, 69, 1274, 10.1210/jcem-69-6-1274 · DOI
  39. Franco, 2005, Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial., J Clin Endocrinol Metab, 90, 1466, 10.1210/jc.2004-1657 · DOI
  40. Pasarica, 2007, Effect of growth hormone on body composition and visceral adiposity in middle-aged men with visceral obesity., J Clin Endocrinol Metab, 92, 4265, 10.1210/jc.2007-0786 · DOI
  41. Holdstock, 2003, Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans., J Clin Endocrinol Metab, 88, 3177, 10.1210/jc.2002-021734 · DOI
  42. Mancini, 2006, Effect of gastric bypass on spontaneous growth hormone and ghrelin release profiles., Obesity, 14, 383, 10.1038/oby.2006.51 · DOI
  43. Ram, 2005, Impact of gastric banding on plasma ghrelin, growth hormone, cortisol, DHEA and DHEA-S levels., Obes Surg, 15, 1115, 10.1381/0960892055002329 · DOI
  44. Engström, 2006, Effects of gastric bypass on the GH/IGF-I axis in severe obesity and a comparison with GH deficiency., Eur J Endocrinol, 154, 53, 10.1530/eje.1.02069 · DOI
  45. Mauras, 2005, Are the metabolic effects of GH and IGF-I separable?, Growth Horm IGF Res, 15, 19, 10.1016/j.ghir.2004.12.003 · DOI
  46. De Marinis, 2004, Growth hormone secretion and leptin in morbid obesity before and after biliopancreatic diversion: relationships with insulin and body composition., J Clin Endocrinol Metab, 89, 174, 10.1210/jc.2002-021308 · DOI

Metadata

Authors
Savastano, S., Di Somma, C., Angrisani, L., Orio, F., Longobardi, S., Lombardi, G., & Colao, A.
Affiliations
  • Federico II University Hospital (IT)
  • Department of Molecular and Clinical Endocrinology and Oncology (S.S., C.D.S., F.O., G.L., A.C.), Division of Endocrinology, University Federico II of Naples, 80131 Naples, Italy
  • Department of Surgery (L.A.), S. Giovanni Bosco Hospital of Naples, 80144 Naples, Italy
  • Parthenope University of Naples (IT)
  • Merck Serono S.p.A. (Italy) (IT)
Corresponding author
Colao, Annamaria
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2009-03-01
Volume
94
Issue
3
Pages
817-826
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2008-1476
OpenAlex
W2091733618
Cited by
34
References
55
Citations by year
2026: 1 · 2025: 1 · 2024: 3 · 2023: 1 · 2022: 4 · 2021: 2 · 2019: 3 · 2018: 1 · 2015: 1 · 2014: 7 · 2013: 2 · 2012: 2
FWCI
2.11
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
Università degli Studi di Napoli Federico II
Topics
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
Keywords
growth hormone therapy, recombinant human growth hormone, bariatric surgery, morbid obesity, lean mass loss, appendicular skeletal muscle mass, gastric banding, postoperative weight loss, insulin sensitivity, glucose tolerance, lipid profile, hypocaloric diet, physical activity
MeSH terms
Adolescent, Adult, Body Composition, Energy Metabolism, Female, Humans, Insulin-Like Growth Factor I, Middle Aged, Obesity, Morbid, Laparoscopy, Pilot Projects, Prospective Studies, Gastroplasty, Body Mass Index, Human Growth Hormone

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review